Development of abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor as a secondary hormonal therapy in prostate cancer

Keyphrases

• 17,20-Lyase 100%
• 17α-Hydroxylase 100%
• Abiraterone Acetate 100%
• Adrenal Androgens 66%
• Adrenal Steroids 33%
• Advanced Prostate Cancer 33%
• Androgen Deprivation Therapy 33%
• Androgen Receptor 33%
• Androgen Suppression 33%
• Androgen Synthesis 33%
• Castration-resistant Prostate Cancer 66%
• Hormone-sensitive Prostate Cancer 33%
• Mediated Growth 33%
• Phase I Dose-escalation Trials 33%
• Progressive Disease 33%
• Prostate Cancer 100%
• PSA Decline 33%
• Secondary Hormonal Therapy 100%
• Signaling Pathway 33%
• Small Molecules 33%
• Synthetic Pathway 33%
• Targets for Therapy 33%
• Testosterone 33%
• Toxicity Profile 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Abiraterone Acetate 100%
• Androgen 75%
• Androgen Receptor 25%
• Castration Resistant Prostate Cancer 75%
• Diseases 25%
• Hormone Cancer Therapy 100%
• Lyase Inhibitor 100%
• Prostate Cancer 100%
• Steroid 17alpha Monooxygenase 100%